In the different countries of the world, either there is no regulation at all, or regulation of the regulatory and legal activities related to the use of the CBD is fragmentary. Unlike tetrahydrocannabinol, natural CBD is not a psychotropic and can not harm the human body.
Cannabidiol (CBD) is one of the non-psychotropic and intoxicating cannabinoids, which can be obtained in a significant amount from the green mass of technical hemp. For the last 5 years, this cannabinoid has enjoyed unflagging interest from the world's largest pharmaceutical companies, as well as private investors working in various areas of management, not related to medicine. CBD does not only have a huge amount of therapeutic and medicinal properties, but besides all this, it has no side effects even when it is used in large doses.
CBC is one of the main cannabinoids that can be extracted from industrial crops of low-cannabis hemp. At the moment, the above substance in the upper third of the plant is present in concentrations ranging from 0.5 to 4%. The ability to extract CBD from leaves and inflorescences of technical hemp makes it possible to use not only a seed, fiber or kostra as a raw material, but also the green mass of the plant as an extremely high-margin raw material. It is on the way to maximize the use of all parts of the plant at this time are all cannabis growers in Europe, Australia, Asia, North and South America. It should be noted that the income derived from the use of leaves and inflorescences of cannabis, often exceeds the earnings that the farmer receives from the sale of grains or hemp trusts, fiber or kostra.
Worldwide brands are increasingly using cannabidiol (CBD) as a food supplement, or it is included in the formulation of specialized or conventional food products, thereby generating the possibility of creating new jobs in depressed agricultural regions of economically developed countries involved in cannabis cultivation. The world's largest pharmaceutical companies not only intensively study the healing properties of cannabidiol, but also actively use it and other non-narcotic cannabinoids to create new drugs. Another extremely intensively developing business is the use of cannabidiol in cosmetics, in elite animal feeds, as well as specialized refueling of electronic cigarettes. The wide distribution of CBD in various products on the market allows citizens of economically developed countries to use this non-narcotic cannabinoid for improving the body by using it through conventional products, cosmetics, etc.
Advantages and possible side effects of CBD in various concentrations and applications
Numerous scientific studies not only clearly demonstrated, but also proved the therapeutic potential of cannabidiol in the treatment of a significant number of diseases or the prevention of painful symptoms. CBD in modern medical practice is actively used to treat the following diseases: anxiety disorders (posttraumatic syndrome, Alzheimer's disease), obesity, epilepsy, dystonia, diabetes, oncology, neurodermatitis, etc. Its antibacterial properties can be used to combat various kinds of infections, inflammations, microbes. In particular, cannabidiol is effective in the treatment of various diseases associated with staphylococci, streptococci and even methicillin-resistant Staphylococcus aureus (MRSA).
Another exclusion of cannabidiol is that its therapeutic properties are manifested in extremely low concentrations and small doses. In addition, cannabidiol has excellent physiological effects, antioxidant, neuroprotective, anti-inflammatory properties. For example, CCD is a neuroprotective antioxidant, more powerful than ascorbate (Vitamin C) or tocopherol (Vitamin E). In cosmetic preparations, cannabidiol is used to reduce sebum, or natural cleansing of the sebaceous glands.
A comprehensive review of cannabidiol by various safety criteria demonstrates that even large doses of CBD are safe and well tolerated by humans without any significant side effects. This non-narcotic cannabinoid does not affect such factors as heart rate, blood pressure, body temperature, the activity of the gastrointestinal tract, as well as the psychomotor and cognitive functions of the human body. Since 2011, various clinical trials have been conducted with a wide range of doses of CBD. Studies have confirmed the efficacy of cannabidiol in the treatment of epilepsy and psychosis, while showing better tolerability of CBD and more moderate side effects compared with the classic drugs used to treat these diseases.
The need to resolve legal aspects related to the application of CBD in various spheres of management
At the moment, in the different countries of the world, either there is no regulation at all, or regulation of regulatory and legal activities related to the use of CBD is fragmentary. Unlike tetrahydrocannabinol, natural CBD is not a psychotropic and can not harm the human body. Therefore, it is fair and reasonable that out of 28 EU member states, only in Slovakia, pure cannabidiol has any restrictions for dissemination. However, in the case of cannabis extracts containing CBD, the situation is not so clear, as they may also contain TGK, which is regulated by international and national regulations.
The European Association of Industrial Cannabis (EIHA) supports the initiative to develop harmonized legislation in this area in order to protect the rights of hemp extract consumers, maintain the current double-digit growth rate of the industry, attract new investors and stimulate the market launch and sales of new hemp products. The regulatory framework should avoid any restrictions on the use of pure CBD and clarify at the legislative level that extracts and preparations from technical hemp are not drugs in the territory of all countries that make up the EU.
EIHA opposes attempts by individual pharmaceutical companies to make CBD a prescription drug. This kind of initiative serves the interests of several pharmaceutical companies, damaging the young, dynamically developing CBD industry. Adoption of this kind of legislation on the one hand will severely restrict access to CBD products for many citizens who already use them on the other will destroy entire branches of the CBD industry specializing in CBD products or CBD cosmetics. The European Association of Industrial Cannabis expects that the legislative bodies of the EU countries will not restrict the use of CBD only to pharmaceuticals or medicines. Absolutely there are no weighty reasons for regulating access to CBD due to a wide range of its beneficial physiological effects and an unconditional safety profile.
For different doses and applications of CBD, EIHA offers a three-level control and regulation system
• in large doses, CBD can be a drug and regulated in some way;
• In physiological doses, cannabidiol should be considered as a "product outside the prescription" or a food supplement. This approach is already applied in the EU countries for a significant number of substances - valerian, glucosamine, chondroitin (sulfate), ginkgo biloba, some vitamins and iron products;
• low concentrations and doses of CBD should be tolerated in foods without any restrictions;
• Additional parameters, such as the mechanism of the entry of CCD in the human body, the area of ​​indication of the drug, the maximum single / daily dose and the size of the package can be used later to accurately control the amount of the substance.

Information taken from the site